GSK Plc has agreed to acquire Rapt Therapeutics, a U.S.-based biotech firm focused on inflammatory and immunologic diseases. The deal values Rapt at $2.2 billion, a significant premium for the clinical-stage company. This move strengthens GSK's pipeline in a competitive therapeutic area.

For GSK, the acquisition provides access to Rapt's experimental drug candidates, notably its lead asset targeting chronic inflammatory conditions. This aligns with the pharmaceutical giant's strategy to bolster its immunology portfolio amid patent expirations on older drugs. The transaction underscores the ongoing consolidation in biotech.

Rapt's shareholders will receive cash for their shares, offering a clear exit for investors. The deal's completion, expected later this year, hinges on regulatory approvals. Analysts will watch how quickly GSK can advance Rapt's programs through late-stage trials to generate returns on this investment.